Oncolytic virus clinical trial landscape expands with 100+ companies

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The global oncolytic virus therapy landscape has expanded significantly with more than 100 companies worldwide, such as Theriva Biologics, pursuing clinical or preclinical programs to develop oncolytic virus‑based cancer treatments, according to a new market report. The analysis highlights a robust pipeline encompassing over 110 potential oncolytic virus drug candidates at various stages of development, reflecting increased industry investment in this immunotherapy approach.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE